NICE Announces Second Strike Against Gilenya For Cost-Effectiveness
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE says that additional information provided by Novartis does not satisify its requirement for proof of cost-effectiveness of Gilenya.
You may also be interested in...
German HTA Assessment Knocks Back Gilenya In Europe
IQWiG’s failure to find any added benefit from Novartis’ oral MS drug Gilenya in two out of three of its target patient groups, on the grounds of insufficient evidence, puts pressure on the drug following a similarly negative recommendation by U.K. cost-watchdog NICE at the end of 2011.
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.
Novartis' Gilenya: Down But Not Out With NICE
Novartis faces a setback in the U.K., as NICE refuses to recommend Gilenya to the NHS, citing lack of comparative data and cost.